- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07682909
Prospective, Non-interventional, Multicenter Post-Market Clinical Follow-Up Study (oneKNEE)
oneKNEE - Prospective, Non-interventional, Multicenter Post-Market Clinical Follow-Up Studies
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Safety and Clinical Performance will be observed:
Safety: All adverse device effects: serious and non-serious adverse events with relation to either the product or the surgical procedure.
Clinical Performance: Difference in Oxford Knee Score (OKS) 2 years after implantation compared to preoperative state.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Heike Oberascher
- Telefonní číslo: +49 7461 95
- E-mail: studies@aesculap.de
Studijní záloha kontaktů
- Jméno: Stefan Maenz, Dr.
- Telefonní číslo: +49 7461 95
- E-mail: studies@aesculap.de
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Patient age ≤ 80 years
- Indication for a total knee replacement with one of the variants
- Written informed consent
- Willingness and mental ability to participate at the long-term follow-up examinations
Exclusion Criteria:
- Contraindications acc. to the Instructions for Use (IFU)
- Patient age < 18 years
- Known pregnancy
- BMI > 40
- Secondary gonarthrosis (e.g. rheumatoid arthritis, post-traumatic)
- Patients classified as high risk (ASA class >3)
- Patients with immunodeficiency, i.e. patients currently receiving immunosuppressive therapy or patients with severe immunodeficiency requiring drug therapy
- Preoperative: aHKA > 190° or aHKA < 170°
- Preoperative: aHKA > 190° or aHKA < 170°[KB1.1][HO1.2][KB1.3][HO1.4]
- Patients held in a custodial setting und - Patients in a relationship of dependence on the sponsor, the clinic or the investigator
Studijní plán
Jak je studie koncipována?
Detaily designu
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Safety of the implant
Časové okno: 2 years after implantation
|
Safety in terms of clinical outcome of oneKNEE® All adverse device effects: serious and non-serious adverse events with relation to either the product or the surgical procedure.
|
2 years after implantation
|
|
Clinical Performance in terms of clinical outcome of oneKNEE®
Časové okno: 2 years after implantation
|
Clinical Performance in terms of clinical outcome of oneKNEE®. Difference in Oxford Knee Score (OKS) 2 years after implantation compared to preoperative state. The Oxford Knee Score (OKS) is a validated joint-specific patient-reported outcome measure that is commonly employed to assess the outcome of TKA. It is a 12-item, patient-reported questionnaire originally developed and validated specifically to assess function and pain in patients undergoing TKA. It is short, reproducible, valid and sensitive to clinically important changes over time. OKS ranges from 0 to 48 with 48 being the best outcome. |
2 years after implantation
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Clinical Outcome by evaluating the Oxford Knee Score
Časové okno: V4=3 months post OP, V5= 1year p.OP, V6= 2years p.OP, V7= 5years p.OP, V8= 7years p.OP, V9=10 years p.OP, V10=15 y. p.OP
|
The Oxford Knee Score, OKS is a validated joint-specific patient-reported outcome measure that is commonly employed to assess the outcome of TKA.
It is a 12-item, patient-reported questionnaire originally developed and validated specifically to assess function and pain in patients undergoing TKA.
It is short, reproducible, valid and sensitive to clinically important changes over time.
OKS ranges from 0 to 48 with 48 being the best outcome.
|
V4=3 months post OP, V5= 1year p.OP, V6= 2years p.OP, V7= 5years p.OP, V8= 7years p.OP, V9=10 years p.OP, V10=15 y. p.OP
|
|
Evaluation of Changes in Quality of Life
Časové okno: V1= pre OP, V3= Discharge, V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
The EQ-5D-5L is a standardized instrument used to measure health outcomes. Developed by the EuroQol Group (EQ), it assesses five dimensions (5D) of health: Mobility Self-care Usual activities Pain/discomfort Anxiety/depression Each dimension has five levels (5L) of severity: no problems, slight problems, moderate problems, severe problems, and extreme problems |
V1= pre OP, V3= Discharge, V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Evaluation of Patient Satisfaction by using PROMS: FJS
Časové okno: V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
Forgotten Joint Score (FJS) : A joint-specific questionnaire with the aim to measure PRO of joint disorders . FJS is designed to measure the ability of the patient to "forget" about their problematic joint after treatment. Scale:
|
V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Knee functional outcome
Časové okno: V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
Range of Motion (ROM)
|
V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Knee alignment, measurement of LDFA: Lateral distal femoral angle
Časové okno: V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
LDFA: Lateral distal femoral angle.
The angle between the mechanical axis of the femur and the knee joint line.
Normal values typically range between 85° and 90° Medial proximal tibial angle (MPTA) and lateral distal femoral angle.
|
V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Knee alignment, measurement of MPTA: Medial proximal tibial angle
Časové okno: V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
MPTA: Medial proximal tibial angle.
The angle between the mechanical axis of the tibia and the knee joint line.
Normal values also typically average around 87° ± 3°.
|
V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Knee alignment, measurement of HKA: Hip Knee Angle
Časové okno: V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
HKA: (Hip Knee Angle).
The mechanical angle between the center of the femoral head, the center of the knee, and the center of the ankle.
It represents the overall lower limb alignment (e.g., neutral, varus, or valgus)
|
V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Radiologically relevant findings by using AI
Časové okno: V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
"Image biopsy lab" is a Digital AI platform that supports physicians and healthcare professionals in transforming medical imaging data into diagnostic findings.
|
V4= 3 months post OP, V5= 1 year post OP, V6= 2 years post OP, V7= 5 years post OP, V8= 7 years post OP, V9= 10 years post OP, V10= 15 years post OP
|
|
Adverse events
Časové okno: 15 years
|
Serious and non-serious adverse events (SAE/AE)
|
15 years
|
|
Device deficiencies assessed by Adverse Events
Časové okno: 15 years
|
In any case of Adverse Events marked as "related to the product/device"
|
15 years
|
|
Intraoperative complications
Časové okno: day of surgery
|
day of surgery
|
|
|
Survival of implant components
Časové okno: From V3=Discharge to V10 = 15 years post OP
|
From V3=Discharge to V10 = 15 years post OP
|
|
|
Optional: OrthoPilot® Data
Časové okno: Day of surgery
|
During surgery all data measured and stored by OrthoPilot® the computer assistant (e.g.
time needed for the surgery, alignment of all implant components) will be evaluated.
|
Day of surgery
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Anne Postler, PD Dr. med, Städt. Klinikum Dresden
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- AAG-O-H-25103
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na oneKNEE®
-
Chung-Ang University Hosptial, Chung-Ang University...NeznámýFunkční dyspepsieKorejská republika
-
Sanofi Pasteur, a Sanofi CompanyDokončenoPertussis | Záškrt | ObrnaSpojené státy
-
Dong-A ST Co., Ltd.Dokončeno
-
Chong Kun Dang PharmaceuticalDokončeno
-
Galderma R&DDokončenoAtopická dermatitidaFilipíny, Čína
-
Sanofi Pasteur, a Sanofi CompanyDokončeno
-
Hoffmann-La RocheDokončenoChronická renální anémieBelgie, Brazílie, Spojené království, Srbsko, Španělsko, Německo, Korejská republika, Krocan, Litva, Itálie, Česko, Argentina, Austrálie, Chorvatsko, Francie, Řecko, Izrael, Malajsie, Mexiko, Panama, Filipíny, Polsko, Ruská Federace, Si... a více
-
University Hospital, CaenDokončeno
-
Amir AzarpazhoohInstitut Straumann AGDokončeno